Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy argenx (ARGX) stocks in Canada

Learn how to easily invest in argenx stocks.

argenx is a biotechnology business based in the US. argenx stocks (ARGX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $312.2 – a decrease of 6.74% over the previous week. argenx employs 336 staff and has a trailing 12-month revenue of around $510.1 million.

How to buy shares in argenx

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ARGX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy argenx stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted argenx's stock price?

Since the stock market crash in March caused by coronavirus, argenx's stock price has had significant positive movement.

Its last market close was $291.5, which is 44.73% up on its pre-crash value of $161.1 and 180.96% up on the lowest point reached during the March crash when the stocks fell as low as $103.75.

If you had bought $1,000 worth of argenx stocks at the start of February 2020, those stocks would have been worth $855.27 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,932.65.

argenx stock price (NASDAQ:ARGX)

Use our graph to track the performance of ARGX stocks over time.

argenx shares at a glance

Information last updated 2022-01-10.
Latest market close$291.50
52-week range$248.21 - $382.15
50-day moving average $311.41
200-day moving average $302.21
Wall St. target price$381.22
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-7.24

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Feature Table description
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks (total value up to $9,000) when you deposit and trade $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of at least $200/month. Valid until March 1, 2022.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

argenx price performance over time

Historical closes compared with the close of $291.5 from 2022-01-14

1 week (2022-01-07) -6.74%
1 month (2021-12-16) -1.90%
3 months (2021-10-15) -0.76%
6 months (2021-07-16) -5.79%
1 year (2021-01-15) 4.40%
2 years (2020-01-16) 94.28%
3 years (2019-01-16) 185.23%
5 years (2017-01-12) N/A

argenx financials

Revenue TTM $510.1 million
Gross profit TTM $-270,945,000
Return on assets TTM -4.36%
Return on equity TTM -14.14%
Profit margin -73.05%
Book value $57.43
Market capitalisation $15.9 billion

TTM: trailing 12 months

argenx share dividends

We're not expecting argenx to pay a dividend over the next 12 months.

argenx share price volatility

Over the last 12 months, argenx's shares have ranged in value from as little as $248.21 up to $382.15. A popular way to gauge a stock's volatility is its "beta".

ARGX.US volatility(beta: 0.89)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while argenx's is 0.8859. This would suggest that argenx's shares are less volatile than average (for this exchange).

argenx overview

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S. À. R.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site